These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26000884)

  • 21. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.
    Lobba ARM; Carreira ACO; Cerqueira OLD; Fujita A; DeOcesano-Pereira C; Osorio CAB; Soares FA; Rameshwar P; Sogayar MC
    PLoS One; 2018; 13(6):e0199254. PubMed ID: 29949609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors.
    Tell RW; Horvath CM
    Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12787-92. PubMed ID: 25139989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triggering a switch from basal- to luminal-like breast cancer subtype by the small-molecule diptoindonesin G via induction of GABARAPL1.
    Fan M; Chen J; Gao J; Xue W; Wang Y; Li W; Zhou L; Li X; Jiang C; Sun Y; Wu X; Wu X; Ge H; Shen Y; Xu Q
    Cell Death Dis; 2020 Aug; 11(8):635. PubMed ID: 32801338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of annexin A1 in expression of matrix metalloproteinase-9 and invasion of breast cancer cells.
    Kang H; Ko J; Jang SW
    Biochem Biophys Res Commun; 2012 Jun; 423(1):188-94. PubMed ID: 22640735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Annexin A1 expression and its prognostic significance in human breast cancer.
    Wang LP; Bi J; Yao C; Xu XD; Li XX; Wang SM; Li ZL; Zhang DY; Wang M; Chang GQ
    Neoplasma; 2010; 57(3):253-9. PubMed ID: 20353277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers.
    Luthra R; Singh RR; Luthra MG; Li YX; Hannah C; Romans AM; Barkoh BA; Chen SS; Ensor J; Maru DM; Broaddus RR; Rashid A; Albarracin CT
    Oncogene; 2008 Nov; 27(52):6667-78. PubMed ID: 18663355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
    Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Annexin A1 Is Required for Efficient Tumor Initiation and Cancer Stem Cell Maintenance in a Model of Human Breast Cancer.
    Johnstone CN; Tu Y; Langenbach S; Baloyan D; Pattison AD; Lock P; Britt KL; Lehmann BD; Beilharz TH; Ernst M; Anderson RL; Stewart AG
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis.
    Bist P; Leow SC; Phua QH; Shu S; Zhuang Q; Loh WT; Nguyen TH; Zhou JB; Hooi SC; Lim LH
    Oncogene; 2011 Jul; 30(28):3174-85. PubMed ID: 21383699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma.
    Tang J; Qin Z; Han P; Wang W; Yang C; Xu Z; Li R; Liu B; Qin C; Wang Z; Tang M; Zhang W
    Int J Oncol; 2017 May; 50(5):1839-1847. PubMed ID: 28393205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
    Lo PK; Lee JS; Liang X; Sukumar S
    Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer metastasis to brain results in recruitment and activation of microglia through annexin-A1/formyl peptide receptor signaling.
    Foo SL; Sachaphibulkij K; Lee CLY; Yap GLR; Cui J; Arumugam T; Lim LHK
    Breast Cancer Res; 2022 Apr; 24(1):25. PubMed ID: 35382852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
    Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
    Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
    Dey N; De P; Leyland-Jones B
    Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
    Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
    Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.
    Iglesia MD; Vincent BG; Parker JS; Hoadley KA; Carey LA; Perou CM; Serody JS
    Clin Cancer Res; 2014 Jul; 20(14):3818-29. PubMed ID: 24916698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.